共 34 条
- [21] Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) vs. Dipeptidyl Peptidase 4 Inhibitor (DPP4i) as Initiator Therapy with Type 2 Diabetes on Cardiovascular Outcomes -A Systematic Review and Meta-analysisDIABETES, 2024, 73Shrestha, Abhigan B.Rajak, KripaTummala, NayanikaMaddineni, Gautam
- [22] Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysisJOURNAL OF DIABETES INVESTIGATION, 2024, 15 (03) : 374 - 387Kashiwagi, AtsunoriShoji, ShingoKosakai, YoshinoriYoshinaga, YokoRokuda, Mitsuhiro
- [23] Above-Average Weight Loss at 1 Year Co-occurs with HbA1c Reduction in Patients with Type 2 Diabetes Treated with Exenatide Once-Weekly in a Real-World SettingDIABETES, 2015, 64 : A650 - A650Mcadam-Marx, CarrieHiep NguyenSchauerhamer, MarisaUnni, SudhirSinghal, MukulCobden, David
- [24] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)-Experienced Adults with Type 2 Diabetes (T2D) Switching to Once-Weekly (OW) Semaglutide in a Real-World Setting-SURE Program Post Hoc AnalysisDIABETES, 2023, 72Rudofsky, GottfriedMenzen, MarkusPotier, LouisCatarig, Andrei-MirceaClark, AlicePriyadarshini, PrachiAbreu, Cristina
- [25] Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: A retrospective, real-world studyDIABETES OBESITY & METABOLISM, 2025, 27 (04): : 2086 - 2095Gulati, KunalWijndaele, KatrienWebb, Joannevon Arx, Lill-BrithSeif, MonicaJennison, ThomasGeneidat, AntoniaWild, RosieWood, RobertKhunti, Kamlesh
- [26] Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)-DUAL IX TrialDIABETES, 2018, 67Philis-Tsimikas, AthenaBillings, LianaBusch, Robert S.Portillo, Cristobal MoralesSahay, RakeshHalladin, NatalieJuhl, Ruta GronskyteHarris, Stewart
- [27] Comparative Efficacy of Ertugliflozin (ERTU) plus Sitagliptin (SITA) vs. Other Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) + Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Combinations: Model-Based Meta-analysis (MBMA) of HbA1c LoweringDIABETES, 2019, 68Fediuk, DarylMandema, JaapSweeney, KevinTerra, Steven G.Sahasrabudhe, Vaishali
- [28] Patient-Reported Outcomes (PROs) for Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)-DUAL IX TrialDIABETES, 2018, 67Brod, MerylBillings, Liana K.Busch, Robert S.Harris, StewartPortillo, Cristobal MoralesSahay, RakeshBusk, AnneEggert, SarahHalladin, NataliePhilis-Tsimikas, Athena
- [29] Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated databaseDIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2606 - 2623Anson, MatthewHenney, Alex E.Zhao, Sizheng S.Ibarburu, Gema H.Lip, Gregory Y. H.Cuthbertson, Daniel J.Nabrdalik, KatarzynaAlam, Uazman
- [30] Real-World Health Outcomes of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Glargine 100 U/mL (Gla-100) in Patients with Type 1 (T1D) and Type 2 Diabetes (T2D) in the Canadian LMC Diabetes Patient Registry-The REALITY StudyDIABETES, 2018, 67Abitbol, AlexanderBrown, Ruth E.Jiandani, DishaySauriol, LucAronson, Ronnie